Provided by Tiger Trade Technology Pte. Ltd.

REIN THERAPEUTICS INC

0.3369
-0.0308-8.38%
Post-market: 0.39000.0531+15.76%19:30 EST
Volume:668.75K
Turnover:239.01K
Market Cap:28.82M
PE:-0.21
High:0.3899
Open:0.3575
Low:0.3352
Close:0.3677
52wk High:2.10
52wk Low:0.2844
Shares:85.54M
Float Shares:65.83M
Volume Ratio:0.24
T/O Rate:1.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5693
EPS(LYR):-1.9600
ROE:-100.48%
ROA:-24.60%
PB:3.71
PE(LYR):-0.17

Loading ...

Shares of Rein Therapeutics Down 34% After Q3 Results

THOMSON REUTERS
·
Nov 16

Rein Therapeutics Says 33% Of Evaluable Patients Showed Lung-Function Improvement At Week 12 In Blinded Phase 2 RENEW IPF Data

Benzinga Earnings
·
Nov 16

Rein Therapeutics reports blinded twelve-week observations from RENEW trial

TIPRANKS
·
Nov 16

Rein Therapeutics Q3 Net Loss Per Share Narrows 71% to $0.06

Reuters
·
Nov 16

Rein Therapeutics - Study Achieves 75% Enrollment with 90 Patients Randomized; Topline Data Expected in 2027

THOMSON REUTERS
·
Nov 16

Rein Therapeutics Inc Q3 Net Income USD -5.537 Million

THOMSON REUTERS
·
Nov 16

Rein Therapeutics Inc Q3 Basic EPS USD -0.06

THOMSON REUTERS
·
Nov 16

Rein Therapeutics Inc Q3 Income from Operations USD -6.999 Million

THOMSON REUTERS
·
Nov 16

Rein Therapeutics - 33% of Evaluable Patients Show Improvement in Forced Vital Capacity at Week 12

THOMSON REUTERS
·
Nov 16

Rein Therapeutics - Low Discontinuation Rates and no Serious Adverse Events Related to Study Treatment

THOMSON REUTERS
·
Nov 16

Rein Therapeutics Announces Preliminary Blinded Phase 2 Renew Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Results

THOMSON REUTERS
·
Nov 16

Press Release: Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Results

Dow Jones
·
Nov 16

Rein Therapeutics Inc Expected to Post a Loss of 10 Cents a Share - Earnings Preview

Reuters
·
Nov 11

H.C. Wainwright Reaffirms Their Buy Rating on Rein Therapeutics (RNTX)

TIPRANKS
·
Sep 22

Rein Therapeutics Releases Scientific Presentation on IPF Candidate LTI-03

Reuters
·
Sep 05

Rein Therapeutics Presents Late-Breaking ERS Poster on Inhaled LTI-03 Idiopathic Pulmonary Fibrosis Dose-Escalation Trial

Reuters
·
Sep 04

Rein Therapeutics to Present at Upcoming September Investor Conferences

GlobeNewswire
·
Sep 04

Rein Therapeutics Faces NASDAQ Delisting Notice After Shares Trade Below $1 Bid Threshold

Reuters
·
Aug 28

Rein Therapeutics - Enrolling Patients in Phase 2 Renew Trial for Lti-03; Interim Data Expected H2 2026

THOMSON REUTERS
·
Aug 20

Rein Therapeutics Receives U.S. FDA Fast Track Designation for Lti-03 in Idiopathic Pulmonary Fibrosis

THOMSON REUTERS
·
Aug 20